Biomarkers hold immense potential for the future of medicine, enabling more efficient and better-targeted treatments. Most coverage of novel biomarkers to date has been focused on how a patient’s genetic signature can indicate their susceptibility to a disease, but there is a world of other biological and environmental information that can impact how patients respond to treatments. In this blog, SCIEX’s Aaron Hudson explains how non-genetic biomarkers have a key role to play in reaching the goal of truly precise medicine.
Cell-Free Technology is taking a unique approach to protein technology with their BioBits initiative, which they say combines the ease of use of a digital design tool with the detailed scientific validation provided by a CRO. We catch up with Cell-Free CEO Tom Meany to discuss the new technology.Read More
A clinical trial has been launched to identify urine-based biomarkers which indicate lung flare-ups in cystic fibrosis. Researchers believe point-of-care monitoring will help people get treatment faster, improve patient outcomes and reduce healthcare costs.Read More
New tools are enabling researchers to explore individual cells with unprecedented clarity, allowing RNA and protein expression levels to be simultaneously analyzed. In this blog, Brian Lilhanand, Global Platform Leader, Single Cell Multiomics, at BD, discusses how BD’s new AbSeq Assay can provide this targeted profiling and benefit immunology researchers.
Following the recent FDA approval of a procalcitonin assay, we spoke with a representative from Fujirebio Diagnostics, Inc. to learn how measuring this important biomarker will improve the healthcare landscape.Read More
Determining Prognostic Significance of Biomarkers for Risk Stratification of Early Stage Lung CancerBlog
During this year’s AACR Annual Meeting we spoke to Dr. Delphine Lissa and Dr. Ana Robles from the National Cancer Institute to learn more about the team’s most recent study on the use of two specific biomarkers for risk stratification of stage I lung cancer patients.Read More
Understanding the proteome is a fundamental challenge of biology. Here, Bruker Daltonics' Gary Kruppa and Scarlet Koch outline a new method, Parallel Accumulation Serial Fragmentation (PASEF) that offers faster, more sensitive and more robust proteome analysis, giving scientists the potential to discover low-level, biologically significant proteins and validate them in research.Read More
Native Mass Spectrometry (MS) can be used to examine proteins in their natural, folded forms. In this blog, Marshall Bern, Ph.D., the Vice President of Research and Co-Founder of Protein Metrics, discusses how advances in this technique are being paired with cutting-edge charge deconvolution algorithms to improve analysis of antibodies and plasma glycoproteins.Read More